



Correction to: Phosphorylation of pericyte FAK-Y861 affects tumour cell apoptosis and tumour blood vessel regression

Delphine M. Lees¹ · Louise E. Reynolds¹ · Ana Rita Pedrosa¹ · Marina Roy-Luzarraga¹ · Kairbaan M. Hovidala-Dilke¹

Published online: 4 July 2021
© The Author(s) 2021

Correction to: *Angiogenesis*
<https://doi.org/10.1007/s10456-021-09776-8>

In the original publication, Fig. 1 and Fig. 4 were published incorrectly. The correct figures are provided in this correction.

The original article has been corrected.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing,

adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

The original article can be found online at <https://doi.org/10.1007/s10456-021-09776-8>.

✉ Kairbaan M. Hovidala-Dilke
k.hovidala-dilke@qmul.ac.uk

¹ Adhesion and Angiogenesis Laboratory, Centre for Tumour Microenvironment, Barts Cancer Institute – a CR-UK Centre of Excellence, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London EC1M 6BQ, UK




Fig. 1 LLC tumour growth and angiogenesis are reduced in $Pdgfr\beta Cre+;FAK^{Y861F/Y861F}$ mice. **a** $Pdgfr\beta Cre+;FAK^{WT/WT}$, $Pdgfr\beta Cre+;FAK^{Y397F/Y397F}$ and $Pdgfr\beta Cre+;FAK^{Y861F/Y861F}$ mice were born at normal male:female ratios; **b** Mendelian ratios with **c** similar body weights. Pie chart in **a** represents percentage male:female ratio, in **b** represents % Cre+ and Cre- mice born to each genotype ($n=60$ mice/genotype). **d** Western blotting of primary pericytes isolated from $Pdgfr\beta Cre+;FAK^{WT/WT}$, $Pdgfr\beta Cre+;FAK^{Y397F/Y397F}$ and $Pdgfr\beta Cre+;FAK^{Y861F/Y861F}$ mice confirmed reduced levels of p-Y397 and pY861-FAK in FAKY397F and FAKY861F pericytes, respectively. **e** pY861-FAK levels are significantly reduced in Y397F pericytes, $n=2$ independent lysates/genotype. Bar chart represents mean pY861-FAK levels + sd. $*P=0.0155$. GAPDH act as loading control. **f** pY416-Src levels are significantly reduced in Y397F-FAK pericytes. Blots shows pY416-Src, total Src and GAPDH loading control. **g** In vivo tumour growth was significantly reduced only in $Pdgfr\beta Cre+;FAK^{Y861F/Y861F}$ mice. Graphs represent mean tumour volume \pm s.e.m.; $n=15$ $Pdgfr\beta Cre+;FAK^{WT/WT}$ mice, 14 $Pdgfr\beta Cre+;FAK^{Y397F/Y397F}$ mice and 11 $Pdgfr\beta Cre+;FAK^{Y861F/Y861F}$ mice. $****P<0.0001$. Two-sided Mann–Whitney U rank sum test. **h** Tumour blood vessel density was significantly reduced only in $Pdgfr\beta Cre+;FAK^{Y861F/Y861F}$ mice. Bar charts represent mean blood vessel density + s.e.m. $*P=0.0498$; ns, not significant; $n=6$ $Pdgfr\beta Cre+;FAK^{WT/WT}$ tumours, 6 $Pdgfr\beta Cre+;FAK^{Y397F/Y397F}$ tumours and 5 $Pdgfr\beta Cre+;FAK^{Y861F/Y861F}$ tumours. Two-sided Student's t -test. Representative endomucin stained LLC tumour sections are shown for each genotype. Scale bar, 50 μ m




Fig. 4 FAK-Y861F pericytes induce apoptosis in LLC tumour cells. **a** R&D proteome profiler array using lysates from FAK-WT, FAK-Y397F and FAK-Y861F pericytes. Representative dots of differentially expressed proteins are given. Bar charts show mean fold change in protein expression relative to levels in WT. $N=2$ dots from 1 experiment. **b** Lewis lung carcinoma (LLC) cells incubated with conditioned medium (CM) from pericytes plus or minus recombinant MCP-1. Treatment with FAK-Y861F pericyte CM increased LLC apoptosis, compared with CM from FAK-WT pericytes. This effect was rescued upon treatment with MCP-1 (10 and 50 ng/ml). Bar chart represents % TUNEL-positive cells \pm s.e.m. Representative images show effect of CM and MCP-1 on LLC cells. *Arrows*, TUNEL-positive cells. $*P < 0.05$. One-way ANOVA. $N=5-11$ fields of view/genotype. Scale bar, 500 μ m. **c** Early and late stage tumours from *Pdgfr β Cre+;FAK^{Y861F/Y861F}* mice had significantly larger TUNEL-positive areas than tumours from *Pdgfr β Cre+;FAK^{WT/WT}* and *Pdgfr β Cre+;FAK^{Y397F/Y397F}* mice. Bar chart shows % TUNEL-positive area/tumour \pm s.e.m. $***P=0.0012$, $*P=0.0464$; ns, not significant; $n=6$ *Pdgfr β Cre+;FAK^{WT/WT}* mice, 8 *Pdgfr β Cre+;FAK^{Y397F/Y397F}* mice and 6 *Pdgfr β Cre+;FAK^{Y861F/Y861F}* mice. Two-way ANOVA. Representative images show TUNEL-positive staining in tumours. Scale bar, 2.5 mm. **d** LLC cells incubated with CM from pericytes treated with Src siRNA, non-specific scrambled siRNA (Scr) or transfection reagent (NT). CM from non-treated (NT) Y861F had a significantly higher effect on LLC apoptosis compared with CM from either WT or Y397F pericytes. Knockdown of Src in both WT and Y397F pericytes significantly increased LLC apoptosis. Src knockdown in Y861F pericytes did not increase LLC apoptosis above control levels. Bar chart represents % TUNEL-positive cells \pm s.e.m. $***P=0.0006$, $*P=0.0196$ One-way ANOVA. $***P=0.0006$ WT NT vs. 861F NT, $*P=0.03$ (Y397F NT vs. Y861F NT). Two-sided students *t* test. $N=10-23$ fields of view. Scale bar, 500 μ m; *arrows* in **b** and **d** indicate TUNEL-positive cells

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.